Frontiers in physiology · 2025
Effects of bisoprolol combined with torasemide on cardiac electrophysiology in patients with acute myocardial infarction and heart failure.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jing Li, Shi Qiangwei, Zhao Shihao
Аннотация
OBJECTIVE: This paper aims to assess the impact of bisoprolol combined with torasemide on cardiac electrophysiological parameters in acute myocardial infarction (AMI) patients complicated by heart failure (HF).
METHODS: A total of 140 AMI-HF patients were randomized to either the control group (bisoprolol alone for 3 months, n = 70) or an experimental group (bisoprolol for 3 months plus torasemide for 2 weeks, n = 70). The corrected QT (QTc) interval, QT dispersion, B-type natriuretic peptide (BNP) levels, left ventricular ejection fraction (LVEF), serum creatinine, serum potassium, New York Heart Association (NYHA) classification, Borg dyspnea score, lower-limb edema resolution, systolic/diastolic blood pressure (SBP/DBP), heart rate (HR), incidence of ventricular arrhythmia (VA) and atrial flutter/fibrillation (AFL/AF), and cardiovascular and all-cause mortality were evaluated.
RESULTS: Both groups demonstrated statistically significant reductions in QTc interval, QT dispersion, BNP, NYHA class, Borg score, SBP, DBP, HR, along with increased LVEF at 2 weeks and 3 months post-treatment versus baseline, with the experimental group showing moderate improvement at 2 weeks post-treatment in all parameters than the control group (P < 0.05). The experimental group had high serum potassium levels and a greater rate of lower-limb edema-resolution at 2 weeks post-treatment than the control group (P < 0.05). No significant differences were observed between groups in cardiovascular or all-cause mortality (P > 0.05).
CONCLUSION: Bisoprolol combined with torasemide improves cardiac electrophysiological parameters, cardiac function, symptoms, and hemodynamics in AMI-HF patients as early as 2 weeks into treatment.
METHODS: A total of 140 AMI-HF patients were randomized to either the control group (bisoprolol alone for 3 months, n = 70) or an experimental group (bisoprolol for 3 months plus torasemide for 2 weeks, n = 70). The corrected QT (QTc) interval, QT dispersion, B-type natriuretic peptide (BNP) levels, left ventricular ejection fraction (LVEF), serum creatinine, serum potassium, New York Heart Association (NYHA) classification, Borg dyspnea score, lower-limb edema resolution, systolic/diastolic blood pressure (SBP/DBP), heart rate (HR), incidence of ventricular arrhythmia (VA) and atrial flutter/fibrillation (AFL/AF), and cardiovascular and all-cause mortality were evaluated.
RESULTS: Both groups demonstrated statistically significant reductions in QTc interval, QT dispersion, BNP, NYHA class, Borg score, SBP, DBP, HR, along with increased LVEF at 2 weeks and 3 months post-treatment versus baseline, with the experimental group showing moderate improvement at 2 weeks post-treatment in all parameters than the control group (P < 0.05). The experimental group had high serum potassium levels and a greater rate of lower-limb edema-resolution at 2 weeks post-treatment than the control group (P < 0.05). No significant differences were observed between groups in cardiovascular or all-cause mortality (P > 0.05).
CONCLUSION: Bisoprolol combined with torasemide improves cardiac electrophysiological parameters, cardiac function, symptoms, and hemodynamics in AMI-HF patients as early as 2 weeks into treatment.